. OSE Immunotherapeutics Sylvie Détry Sylvie.detry@ose-immuno.com +33 153 198 757 French Media: FP2COM Florence Portejoie fportejoie@fp2com.fr +33 607 768 283 The company's immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto . The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. OSE Immunotherapeutics Receives New European Patent Notice of Allowance ... With ISO . Analyse graphique de Ose Immuno par Boursier.com - Cotation en temps réel Authorship note: SC, BV, and NP contributed equally to this work as co-senior authors. Multivariate association analysis to characterise the immuno-behavioural covariation. Mise à disposition des documents préparatoires à l'Assemblée générale mixte du 23 juin 2022 Nantes, France - 2 juin 2022, 18 heures - OSE Immunotherapeutics SA (ISIN: FR0012127173; Phone: 33..228.291.010; Email: nicolas.poirier@ose-immuno.com. OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. Presentations to focus on CLEC-1, novel myeloid immune checkpoint target for cancer immunotherapyNANTES, France, May 11, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) has been invited to provide an update on its R&D programs in immuno-oncology at two dedicated international conferences in May and June. Its balanced. NANTES, France, May 23, 2022--Regulatory News: OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale), today announced four poster presentations* featuring neoepitope combination Tedopi® in various cancer indications at the American Society of Clinical Oncology (ASCO .